The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer
Jazyk angličtina Země Irsko Médium print-electronic
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi
PubMed
29728273
DOI
10.1016/j.radonc.2018.03.003
PII: S0167-8140(18)30135-X
Knihovny.cz E-zdroje
- Klíčová slova
- Cervical cancer, Follow-up, Guidelines, Management, Staging,
- MeSH
- gynekologie metody normy MeSH
- konsensus MeSH
- laboratorní medicína metody normy MeSH
- lékařská praxe založená na důkazech MeSH
- lidé MeSH
- nádory děložního čípku patologie radioterapie terapie MeSH
- radiační onkologie metody normy MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- směrnice pro lékařskou praxi MeSH
- Geografické názvy
- Evropa MeSH
BACKGROUND: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE: The European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.
Asklepios Hambourg Altona and University of Cologne Medical Faculty Department of Gynecology Germany
Department of Oncology Aarhus University Denmark
Department of Pathology Belfast Health and Social Care Trust United Kingdom
Department of Radiation Oncology Leiden University The Netherlands
Department of Radiation Oncology Tata Memorial Hospital Mumbai India
Department of Radiotherapy Institut Gustave Roussy Villejuif France
Department of Radiotherapy Medical University of Vienna Austria
Dresden University TU Dresden Germany
Fondazione IRCCS Istituto Nazionale Tumori Milan Italy
General Hospital Graz Sued West Austria
Institut Bergonié Bordeaux France
Istituto Nazionale per lo Studio e la Cura dei Tumori FondazioneG Pascale IRCCS Naples Italy
Lausanne University Switzerland
Medical University of Graz Austria
Queen Elizabeth Hospital Gateshead United Kingdom
University College Hospital London United Kingdom
University Hospital Careggi Florence Italy
Citace poskytuje Crossref.org
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
